During Wednesday’s Current trade, Shares of Towers Watson & Co (NASDAQ:TW), lost -0.93% to $123.97.
Global professional services company Towers Watson (TW) has introduced Towers Watson DataValidator, a data validation and transformation software solution that assists insurers use their data more efficiently across financial modeling analytics, pricing applications and risk administration.
DataValidator assists insurers meet evolving regulatory data quality requirements against recently’s increasingly challenging timetables. The solution provides a quick and comprehensive data quality assessment while providing thorough audit trails necessary for mandatory governance and audit readiness.
DataValidator is developed, maintained and supported by Towers Watson. It operates with Towers Watson risk software products and third-party software solutions.
Towers Watson & Co., a professional services company, provides human capital and financial consulting services worldwide. The company’s Benefits segment provides benefits consulting and administration services, such as retirement solutions, which provides actuarial and consulting services for large defined benefit and defined contribution plans, counting consulting on plan design, funding, and risk administration strategies; health and group benefits services, such as plan administration consulting across the health and group benefit programs, counting health, dental, disability, life, and other coverage.
Shares of Allergan PLC (NYSE:AGN), declined -1.32% to $313.29, during its current trading session.
Allergan plc (AGN) stated continued exceptional performance with net revenue increasing 116 percent to $5.76 billion for the quarter ended June 30, 2015, contrast to $2.67 billion in the second quarter 2014. On a non-GAAP basis, diluted earnings per share raised 29 percent to $4.41 for the second quarter 2015, contrast to $3.42 in the second quarter 2014. GAAP loss per share for the second quarter 2015 was $0.80, contrast to GAAP income per diluted share of $0.28 in the preceding year period. GAAP results were influenced by amortization, in-process research and development impairments, acquisition-related expenses, acquisition accounting valuation related expenses and severance and integration costs associated with attained businesses, mainly the acquisitions of Allergan on March 17, 2015 and Forest Laboratories on July 1, 2014.
Other Operating Results
For the second quarter 2015, non-GAAP gross margin was 72.3 percent contrast to 56.3 percent in the second quarter of 2014, reflecting the impact of the Allergan acquisition. Total non-GAAP SG&A as a percent of non-GAAP revenue for the second quarter 2015 was 21.7% contrast to 18.7% in the preceding year period. For the second quarter 2015, non-GAAP R&D spending was $406.0 million contrast to $184.8 million in the preceding year. Adjusted EBITDA raised 203 percent to $2.61 billion in the second quarter of 2015, contrast to $862.0 million for the second quarter 2014. Cash flow from operations for the second quarter of 2015 was $1.4 billion and cash and marketable securities were $1.5 billion as of June 30, 2015.
Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. The North American Brands segment provides patented and off-patent trademarked pharmaceutical products primarily under the Dalvance, Bystolic, Canasa, Carafate, Daliresp, Fetzima, Linzess, Namenda, Namenda XR, Saphris, Teflaro, Viibryd, Actonel, Asacol HD, Atelvia, Delzicol, Doryx, Estrace Cream, Enablex, Lo Loestrin Fe, and Minastrin 24 Fe brands.
Molson Coors Brewing Company (NYSE:TAP), during its Wednesday’s current trading session decreased -0.41% to $72.22.
Molson Coors Brewing Company (TAP) declared that consumer product executive Mary Lynn Ferguson-McHugh will join its board of directors, effective right away.
Ferguson-McHugh is the Group President of Global Family Care for Procter & Gamble Company (PG), one of the world’s largest makers of consumer packaged goods. P&G has one of the strongest portfolios of trusted, quality, leadership brands, counting Always, Bounty, Charmin, Crest, Gillette, Olay, Oral-B, Pampers, Pantene and Tide.
Molson Coors Brewing Company manufactures and sells beer and other beverage products. The company sells its products under the Coors Light, Molson Canadian, Carling, Carling Black Label, Coors Altitude, Coors Banquet, Creemore Springs, the Granville Island, Keystone Light, Mad Jack, Molson Canadian 67, Molson Canadian Cider, Molson Dry, Molson Export, Pilsner, and the Rickard’s family brands in Canada; and brews or distributes under the Amstel Light, Heineken, Murphy’s, Newcastle Brown Ale, Strongbow cider, Desperados, Dos Equis, Moretti, Sol, Tecate, Miller Chill, and Miller Genuine Draft brands. It also sells various brands in the United States and Puerto Rico, such as Coors Light, Miller Lite, Batch 19, Blue Moon, Coors Banquet, Coors Non-Alcoholic, Grolsch, Hamm’s, Henry Weinhard’s, Icehouse, Keystone, Leinenkugel’s brands, Mickey’s, Miller Fortune, Miller Genuine Draft, Miller High Life, Milwaukee’s Best, Olde English 800, Peroni Nastro Azzurro, Pilsner Urquell, Sharp’s non-alcoholic, Smith & Forge, St. Stefanus, Steel Reserve, Third Shift, Worthington’s, and hard cider brands; and brews or distributes under the George Killian’s Irish Red, Redd’s, Foster’s, and Molson brands.
Finally, Ross Stores, Inc. (NASDAQ:ROST), decreased -1.47%, to $53.03.
Ross Stores, Inc. (ROST) will declare its second quarter 2015 earnings results on Thursday, August 20, 2015. A press release will be sent out at about 4:00 p.m. Eastern time.
Ross Stores, Inc., together with its auxiliaries, operates off-price retail apparel and home fashion stores under the Ross Dress for Less and dd’s DISCOUNTS brand names in the United States. It primarily offers apparel, accessories, footwear, and home fashions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
